|
ZL-1310 Clinical Trials
4 actively recruiting trials across 4 locations
No change since August 2026
Pipeline
Phase 1: 2Phase 3: 1Phase 1/2: 1
Top Sponsors
- Zai Lab (Shanghai) Co., Ltd.3
- Amgen1
Indications
- Cancer4
- Lung Cancer3
- Small Cell Lung Cancer2
- SCLC1
- Solid Tumors1
Goodyear, Arizona1 trial
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
City of Hope Cancer Center Phoenix
Phase 1
Duarte, California1 trial
Phase 1
La Jolla, California1 trial
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
University of California San Diego
Phase 3
San Francisco, California1 trial
A Study of ZL-1310 in Participants With Selected Solid Tumors
University of California San Francisco/Helen Diller Family Comprehensive Cancer Center
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.